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Introduction {#jcsm12068-sec-0005}
============

Skeletal muscle wasting has been frequently observed after stroke.[1](#jcsm12068-bib-0001){ref-type="ref"} Already within 4 h after cerebral damage an initial reduction of motoneurons in the musculature of paretic limb is observed[2](#jcsm12068-bib-0002){ref-type="ref"} that persists in the chronic phase after stroke.[3](#jcsm12068-bib-0003){ref-type="ref"} Loss of muscle innervation leads to muscular weakness, inactivity, and immobilization and results in muscle atrophy. Within the first week after stroke muscle weakness occurs also in the non‐paretic limb.[4](#jcsm12068-bib-0004){ref-type="ref"} Decline of muscle mass has been observed in stroke patients within first three weeks after hemiparetic stroke.[5](#jcsm12068-bib-0005){ref-type="ref"} Further, patients who are not able to relearn walking within 2 months after stroke revealed similar lean mass reduction in paretic and non‐paretic leg.[6](#jcsm12068-bib-0006){ref-type="ref"} A combination of mechanisms, including immobilization, disuse, inflammation, metabolic, and neurovegetative imbalance after stroke, results frequently in muscle wasting and may progress to the stroke‐related sarcopenia.[1](#jcsm12068-bib-0001){ref-type="ref"}, [7](#jcsm12068-bib-0007){ref-type="ref"} The presence of stroke‐specific sarcopenia has been proposed from experimental[8](#jcsm12068-bib-0008){ref-type="ref"} and clinical data.[9](#jcsm12068-bib-0009){ref-type="ref"}, [10](#jcsm12068-bib-0010){ref-type="ref"}

Progressive degradation of muscle mass was termed as 'sarcopenia' and was originally observed in relationship to aging.[11](#jcsm12068-bib-0011){ref-type="ref"} The prevalence of sarcopenia is about 5 to 10% in persons over 65 years of age.[12](#jcsm12068-bib-0012){ref-type="ref"} Numerous factors such as malnutrition,[13](#jcsm12068-bib-0013){ref-type="ref"} immobilization and disuse,[14](#jcsm12068-bib-0014){ref-type="ref"} hormonal imbalance etc. are discussed in the multifactorial aetiology of sarcopenia.[15](#jcsm12068-bib-0015){ref-type="ref"}, [16](#jcsm12068-bib-0016){ref-type="ref"}, [17](#jcsm12068-bib-0017){ref-type="ref"}, [18](#jcsm12068-bib-0018){ref-type="ref"} In aging loss of motoneurons has been proposed as pathogenic and contributing to the developing of sarcopenia.[19](#jcsm12068-bib-0019){ref-type="ref"}, [20](#jcsm12068-bib-0020){ref-type="ref"}

Recently, C‐terminal Agrin Fragment (CAF) has been proposed as a potential marker for sarcopenia caused by degeneration of the neuromuscular junctions (NMJs) in elderly.[21](#jcsm12068-bib-0021){ref-type="ref"} Agrin is a heparin sulphate proteoglycan with a molecular weight of 225 kDa, which is considered as a key organizer of postsynaptic differentiation at NMJs.[22](#jcsm12068-bib-0022){ref-type="ref"}, [23](#jcsm12068-bib-0023){ref-type="ref"}, [24](#jcsm12068-bib-0024){ref-type="ref"} Proper clustering of acetylcholine receptors (AChR) at post‐synaptic basal lamina depends on agrin‐mediated signalling.[22](#jcsm12068-bib-0022){ref-type="ref"}, [25](#jcsm12068-bib-0025){ref-type="ref"} Proteolytic cleavage of agrin by neuronal protease neurotrypsin at NMJs triggers inactivation and destabilization of the NMJ with subsequent muscle degradation. A sarcopenic phenotype has been observed in transgenic mouse with neurotrypsin overexpression.[26](#jcsm12068-bib-0026){ref-type="ref"} In human plasma two stable and bio‐inactive circulating fragments of agrin---AgrinC110 (cleavage at α‐site) and CAF22 (cleavage at β‐site) were identified *(Figure* [1](#jcsm12068-fig-0001){ref-type="fig"}).[21](#jcsm12068-bib-0021){ref-type="ref"} It has been shown that elevated CAF22 plasma levels may indicate muscle wasting in pre‐frail community‐dwelling older adults because of degeneration of the NMJ.[27](#jcsm12068-bib-0027){ref-type="ref"} The reduction of CAF22 levels after 12 week power training supports CAF22 as a marker of muscle wasting and the development of sarcopenia. In contrast, a study evaluating an effect of resistance training in older adults revealed elevation of CAF levels following 6‐weeks of training.[28](#jcsm12068-bib-0028){ref-type="ref"}

![Structure and cleavage sites of agrin.](JCSM-7-060-g001){#jcsm12068-fig-0001}

The aim of the present study was to evaluate agrin as a marker of muscle wasting in patients with stroke. Because physical exercise is an effective therapy to prevent muscle wasting,[29](#jcsm12068-bib-0029){ref-type="ref"} we investigated a cohort of stroke patients in the early post stroke rehabilitation. We hypothesized that CAF22 might be a marker of muscle status and function during recovery after paretic stroke. We evaluated CAF22 in relation to changes in muscle mass and functional recovery during early rehabilitation period.

Patients and methods {#jcsm12068-sec-0006}
====================

Study population and enrolment criteria {#jcsm12068-sec-0007}
---------------------------------------

We studied 123 patients (age ranging from 42 to 98 years) with confirmed diagnosis of ischaemic or haemorrhagic stroke. Patients were admitted from October 2011 to August 2013 to neurological rehabilitation centre Brandenburgklinik Bernau, Germany. Clinical and functional examinations were performed at admission and at discharge. Within the early post‐stroke hospitalized rehabilitation programme all patients were on standard medical therapy according to current guideline recommendations (including antiplatelet drugs, statins, angiotensin‐converting enzyme inhibitors, and β‐blocker). Exclusion criteria for this observational study were acute and chronic inflammatory diseases, acute heart failure or myocardial infarction, liver cirrhosis, acute and chronic renal failure and dialysis, immune suppressive therapy, and history of cancer within the last 5 years. Twenty six healthy individuals of similar body mass index (BMI) and age were enrolled used as control group. The research protocol was approved by the local ethics committee, and written informed consent was obtained from all subjects.

Assessment of functional capacity and physical examination {#jcsm12068-sec-0008}
----------------------------------------------------------

Functional independence was assessed using the Barthel index (BI) that addresses basic self‐care and mobility aspects with a score ranging from 0 to 100, where the lowest score indicates greater dependency.[30](#jcsm12068-bib-0030){ref-type="ref"} Assessment of physical status included following testing: the Rivermead motor assessment gross function subscale (RMA) that scores a range of physical activities with increasing complexity from turning over in bed to hop on the affected leg 5 times.[31](#jcsm12068-bib-0031){ref-type="ref"}, [32](#jcsm12068-bib-0032){ref-type="ref"} Arm strength was analysed using the handgrip dynamometer (Saehan Corporation, Korea). The highest of three handgrip measurements was used for analysis.

Body composition {#jcsm12068-sec-0009}
----------------

Body mass index (BMI) was calculated as a ratio of body weight and squared height (kg/m^2^). Body composition was assessed by bioelectrical impedance analysis (BIA) (QuadScan 4000, Bodystat Limited, UK). The principle of BIA analyses is based on measurements of whole body resistance (*R*) and reactance (*Xc*) values[33](#jcsm12068-bib-0033){ref-type="ref"} where *R* reflects conductivity through ionic solutions, and *Xc* reflects dielectric properties of plasma membrane measured as a phase‐shift in current flow at 50 Hz. Phase angle of the whole body (*ϕ*, arc tangent expressing a relationship between Xc and R) is understood as bioimpedance measures of cell membranes of skeletal muscle and as indicator of cellular health.[34](#jcsm12068-bib-0034){ref-type="ref"} BIA measurements were taken in supine position in standard condition as described previously.[35](#jcsm12068-bib-0035){ref-type="ref"}

Blood samples {#jcsm12068-sec-0010}
-------------

Venous blood samples were obtained under standardized conditions after overnight fasting and after 15 min of supine resting in a quiet and air conditioned room. Samples were centrifuged at 3500 rpm for 15 min (2000x g), aliquoted and stored at −80°C until analysis. CAF22 concentrations were measured using a commercially available enzyme‐linked immunosorbent assay (ELISA) kit (NTCAF Elisa Kit; Neurotune, Schieren, Switzerland) as described previously.[36](#jcsm12068-bib-0036){ref-type="ref"} The coefficient of variance of the test is 12.3% maximal deviation for serum and 5.6% maximal deviation for the used calibrator in a combined intra‐ and inter‐plate comparison. For the tested samples, the deviation must have been lower than 20% in each double measurement. The accuracy of the calibrator curve was \>0.98 (Rsqr), and the validated range of detection was 20 pM to 380 pM. In case of higher CFA values, the sample was diluted with PBS and remeasured until the value was within the detection range.

Statistical analysis {#jcsm12068-sec-0011}
--------------------

All variables were tested for normal distribution using the Kolmogorov--Smirnov test. All data were presented as mean values ± standard deviation or as median \[interquartile range, IQR\]. Paired Student t‐test, unpaired Student t‐test, and Mann--Whitney test were used as appropriate. Chi Square test was used to assess categorical distribution between groups. The relationship between variables was analysed by linear and multiple regression analyses. A value of p \< 0.05 was considered statistically significant. For statistical analysis, standard statistical software packages were used (Statview 5.0, SAS Institute, Cary, NC).

Results {#jcsm12068-sec-0012}
=======

Clinical and functional characteristics before and after rehabilitation {#jcsm12068-sec-0013}
-----------------------------------------------------------------------

Functional assessments were performed at admission (23 ± 17 days post stroke) and at discharge from the rehabilitation centre (49 ± 18 days post stroke).

Baseline characteristics of study population groups are shown in *Table* [1](#jcsm12068-tbl-0001){ref-type="table-wrap"}. Patients and healthy controls were of similar age and body mass index (BMI). Fifty‐five per cent of the stroke patients revealed a 2.2% increase of the lean mass at discharge, whereas in the rest of the patients revealed a decline of the body lean mass by 2.6% (*Table* [2](#jcsm12068-tbl-0002){ref-type="table-wrap"}). Physical performance and muscle functional measures were significantly impaired after stroke compared to controls (data shown for the hand grip strength, *Figure* [2](#jcsm12068-fig-0002){ref-type="fig"}) and improved during rehabilitation as assessed by maximum hand grip strength, Barthel index, and Rivermead motor assessment (*Table* [2](#jcsm12068-tbl-0002){ref-type="table-wrap"}). Thus, patients presented better functional performance at discharge from the rehabilitation centre compared to admission.

###### 

Clinical characteristics of study groups

  Parameters                                          Controls n = 26   Patients at admission n = 123                               Patients at discharge n = 123
  --------------------------------------------------- ----------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Age, y                                              67 ± 8            70 ± 11                                                     70 ± 11
  Gender, f/m \[m, %\]                                17/9 \[41\]       49/74 \[60\][\*](#jcsm12068-note-0001){ref-type="fn"}       
  Stroke ischaemic, n \[%\] / haemorrhagic, n \[%\]                     106 \[86\] / 17 \[16\]                                      
  Days after stroke                                                     23 ± 17                                                     49 ± 18[\#\#\#](#jcsm12068-note-0005){ref-type="fn"}
  CAF22, pMol                                         95.7 ± 31.8       134.3 ± 52.3[\*\*\*](#jcsm12068-note-0003){ref-type="fn"}   118.2 ± 42.7[\*](#jcsm12068-note-0001){ref-type="fn"}, [\#\#\#](#jcsm12068-note-0005){ref-type="fn"}
  CAF22, pMol, female                                 102.6 ± 30.7      140.3 ± 51.6[\*\*](#jcsm12068-note-0002){ref-type="fn"}     119.5 ± 35.5[\#\#\#](#jcsm12068-note-0005){ref-type="fn"}
  CAP22, pMol, male                                   82.7 ± 31.2       130.2 ± 52.7[\*\*](#jcsm12068-note-0002){ref-type="fn"}     117.3 ± 47.1[\*](#jcsm12068-note-0001){ref-type="fn"}, [\#\#\#](#jcsm12068-note-0005){ref-type="fn"}
  Change of total CAF22, pMol                                                                                                       −16.1 ± 30.4
  Creatinine, mg/dL                                   0.79 ± 0.14       0.97 ± 0.31[\*\*](#jcsm12068-note-0002){ref-type="fn"}      0.96 ± 0.33
  Sodium, mmol/L                                      141.5 ± 3.3       140.1 ± 4.4                                                 140.3 ± 2.7
  Potassium, mmol/L                                   4.4 ± 0.4         4.4 ± 0.4                                                   4.3 ± 0.5
  Body mass index, kg/m^2^                            25.6 ± 3.3        27.0 ± 4.9                                                  26.0 ± 5.2
  Lean mass, kg                                       46.9 ± 10.1       51.9 ± 11.7[\*](#jcsm12068-note-0001){ref-type="fn"}        51.6 ± 11.3
  Fat mass, kg                                        24.9 ± 6.9        25.0 ± 9.7                                                  23.4 ± 8.8
  Phase angle, *ϕ*                                    5.7 ± 1.1         5.1 ± 1.0[\*\*](#jcsm12068-note-0002){ref-type="fn"}        5.0 ± 1.0[\*\*](#jcsm12068-note-0002){ref-type="fn"}

p \< 0.05,

p \< 0.01,

p \< 0.001 vs. controls;

p \< 0.001 vs. admission

###### 

Parameters of body composition and physical performance at admission and at discharge from the rehabilitation centre

  Parameters                                  At admission (n = 120)   At discharge (n = 120)
  ------------------------------------------- ------------------------ ----------------------------------------------------------
  Lean mass increase, kg, n = 67              50.6 ± 11.8              51.7 ± 11.7[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}
  Lean mass decrease, kg, n = 56              53.2 ± 11.7              51.7 ± 11.4[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}
  Max hand grip strength paretic arm, kg      15.8 ± 11.6              16.0 ± 11.7[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}
  Max hand grip strength nonparetic arm, kg   28.2 ± 11.1              29.6 ± 11.7[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}
  Barthel Index score                         60 ± 22                  73 ± 20[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}
  Rivermead Motor Assessment score            5.3 ± 2.0                7.2 ± 2.2[\*\*\*](#jcsm12068-note-0006){ref-type="fn"}

p \< 0.001 vs. admission

![Hand grip strength of stroke patients compared to healthy controls (\*\*\*p \< 0.001 vs. controls; ^\#\#\#^p \< 0.001 vs. admission).](JCSM-7-060-g002){#jcsm12068-fig-0002}

CAF22 plasma level during rehabilitation {#jcsm12068-sec-0014}
----------------------------------------

At admission, CAF22 serum level was significantly elevated (+26%) in stroke patients compared to controls (p \< 0.001, unpaired t‐test; *Figure* [3](#jcsm12068-fig-0003){ref-type="fig"} *A*). CAF22 level declined subsequently during rehabilitation but remained 17% above the control group at discharge (p \< 0.05; *Figure* [3](#jcsm12068-fig-0003){ref-type="fig"} *A*). The mean change of CAF22 serum level between discharge and admission was expressed as a change of total CAF22 (*Table* [1](#jcsm12068-tbl-0001){ref-type="table-wrap"}). CAF22 serum levels were not significantly different in females compared to male patients (*Table* [1](#jcsm12068-tbl-0001){ref-type="table-wrap"}). However, compared to healthy controls female stroke patients showed 21% higher CAF22 level at admission (*Figure* [3](#jcsm12068-fig-0003){ref-type="fig"} *B*), whereas between male patients and controls this difference was 56% (*Figure* [3](#jcsm12068-fig-0003){ref-type="fig"} *C*). At discharge, CAF22 was 12% higher in female but still 41% higher in male patients compared to controls of the same gender. Thus, CAF22 level rise after stroke seems to be more pronounced in male than in female patients.

![CAF22 plasma level in stroke‐patients at admission to rehabilitation centre and at discharge compared to controls: All patients (A); Female patients (B); Male patients (C) (\*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05 vs. controls; ^\#\#\#^p \< 0.001 vs. admission).](JCSM-7-060-g003){#jcsm12068-fig-0003}

CAF22 and functional performance {#jcsm12068-sec-0015}
--------------------------------

In the linear regression analyses CAF22 levels were associated with BI (r = 0.2, p \< 0.022), RMA score (r = 0.2, p \< 0.05), hand grip strength of the non‐paretic arm (r = 0.2, p \< 0.05), age (r = 0.4, p \< 0.001), and creatinine levels (r = 0.7, p \< 0.001).

In multivariable regression analyses change of CAF22 serum level was independently associated with improvement of the hand grip strength of the paretic arm, but not in the non‐paretic arm in patients who showed increased muscle mass during rehabilitation (*Table* [3](#jcsm12068-tbl-0003){ref-type="table-wrap"} *B*). However, this association was not observed in the whole study cohort (*Table* [3](#jcsm12068-tbl-0003){ref-type="table-wrap"} *A*).

###### 

A). Multiple regression analyses investigating change of hand grip strength during rehabilitation in stroke patients (n = 123)

  Parameter                                                Coefficient   p       r
  -------------------------------------------------------- ------------- ------- ---
  1\. Change of hand grip strength of paretic arm vs.                    0.286   
  Gender                                                   0.059         0.579   
  Age                                                      −0.229        0.035   
  Change of CAF22                                          −0.175        0.097   
  Creatinine                                               −0.102        0.353   
  2\. Change of hand grip strength of nonparetic arm vs.   0.294                 
  Gender                                                   0.141         0.151   
  Age                                                      −0.157        0.120   
  Change of CAF22                                          −0.121        0.223   
  Creatinine                                               −0.189        0.069   

CAF22 levels and phase angle {#jcsm12068-sec-0016}
----------------------------

A strong association between CAF22 level at admission and phase angle (r = −0.351, p \< 0.001) was observed in simple regression analysis. After adjustment for age, creatinine level, and gender this association remained independently significant (*Table* [4](#jcsm12068-tbl-0004){ref-type="table-wrap"}).

###### 

Multiple regression analysis investigating phase angle as a parameter of cell membrane integrity in stroke patients

  Parameter         Coefficient   p        r
  ----------------- ------------- -------- ---
  Phase angle vs.                 0.523    
  Gender            0.170         0.055    
  Age               −0.341        0.0003   
  Creatinine        0.095         0.422    
  CAF22             −0.267        0.026    

Discussion {#jcsm12068-sec-0017}
==========

The major finding of the study is the elevation and dynamic change of CAF22 serum levels in patients after acute stroke. CAF22 serum levels were significantly increased in the subacute phase after stroke. During rehabilitation, an incomplete return of elevated CAF22 levels was observed. CAF22 was associated with parameters of physical and functional performance and with bioelectrical impedance phase angle. Further, an improvement of hand grip strength of the paretic arm during rehabilitation was independently associated with the reduction of CAF22 serum levels in patients who showed an increase of muscle mass during rehabilitation.

We observed elevated CAF22 serum levels at admission to inpatient rehabilitation. CAF22 levels decreased during 4 weeks of a rehabilitation programme but were still higher at discharge compared to healthy subjects. Our findings are in line with previous reports showing a reduction of elevated CAF22 levels after a training programme in a cohort of elder subjects.[27](#jcsm12068-bib-0027){ref-type="ref"} These authors suggested CAF22 as a potential marker of age‐associated sarcopenia caused by the degeneration of the NMJ. In our study patients were admitted to the rehabilitation hospital 3 weeks after stroke. At this time point patients revealed significantly reduced handgrip strength in parallel to elevated CAF22 serum levels. In addition, our analyses have shown an independent association between reduction of CAF22 serum levels and improvement of hand grip strength of the paretic arm in patients with increased muscle mass during rehabilitation. Decreasing of CAF22 levels after 4 weeks of a physical rehabilitation programme might therefore suggest termination of the muscle wasting and reactive NMJs recovery.

Recently, CAF22 has been evaluated as a biomarker of kidney function. Indeed, agrin is expressed in the kidney and CAF22 has been related to the damage of the glomerular basement membrane.[37](#jcsm12068-bib-0037){ref-type="ref"}, [38](#jcsm12068-bib-0038){ref-type="ref"} In our study patients with renal failure as well as with dialysis were excluded. We observed a strong correlation between CAF22 and creatinine, although the reduction of the creatinine serum level at discharge was not significant in contrast to the significant reduction of the CAF22 serum levels. Thus, it is not clear to which extent CAF22 serum levels reflect the kidney function in stroke patients. Yet, a confounder for CAF22 serum levels because of kidney function could not be excluded and may be seen as a limitation of the study.

In addition, the existence of several splicing isoforms of agrin should be considered in the evaluation of CAF22 as a biomarker for sarcopenia.[22](#jcsm12068-bib-0022){ref-type="ref"}, [39](#jcsm12068-bib-0039){ref-type="ref"} Agrin function is highly regulated by alternative splicing and proteolytic processing. Splicing isoforms containing 0 or 4 amino acid inserts at the y splicing site of the LG2 domain and 0, 8, 11, or 19 (8 + 11) amino acid inserts at the z splicing site of the LG3 domain of the C‐terminus have been investigated (*Figure* [1](#jcsm12068-fig-0001){ref-type="fig"}).[23](#jcsm12068-bib-0023){ref-type="ref"}, [40](#jcsm12068-bib-0040){ref-type="ref"} The neural agrin containing 4 and 8 amino acid inserts at the y and z sites, respectively, has a high affinity to the AChR clustering, while muscle agrin and agrin found in other non‐neuronal cells lacks inserts and fails to cluster AChRs.[41](#jcsm12068-bib-0041){ref-type="ref"} However, splicing isoforms of agrin lacking inserts have been found in NMJs (motor neurons, skeletal muscle, and Schwann cells), in the central nervous system and peripheral tissues (lung and kidney).[23](#jcsm12068-bib-0023){ref-type="ref"} The ELISA assay used in the present study predominately identifies the z0 splicing isoform. Previous experiments have shown that the z0 splicing isoform is at least 10--20 folds overrepresented over the insert baring splice isoforms (Western blots and internal analyses). The appearance of the z0 splicing variant of the C‐terminal agrin fragments in blood, however, represents the activity of neurotrypsin.[42](#jcsm12068-bib-0042){ref-type="ref"} Further, a vast amount of z0 isoform of agrin is present on the postsynaptic side, which is also cleavable by neurotrypsin. Muscle agrin is concentrated at the nerve‐induced AChR clusters where it contributes to maturation and stabilization of the receptors.[43](#jcsm12068-bib-0043){ref-type="ref"}, [44](#jcsm12068-bib-0044){ref-type="ref"} Therefore, the postsynaptic muscle agrin is able to liberate CAF22, which may then be secreted and may appear in the blood stream. Thus, we believe that in stroke patients a significant amount of the CAF22 in serum origins from the nervous tissue or postsynaptic tissue because of denervation and degradation of the NMJs. However, optimization of the ELISA assay towards identifying of the neuronal agrin might improve the specificity and sensitivity of the results and may contribute to the establishing of CAF22 as a marker of muscle wasting caused by NMJ degeneration.

Our analyses revealed an independent association of the BIA phase angle with CAF22 levels. Phase angle has been shown in relation to the muscle mass and muscle strength; therefore phase angle represents a simple index of the integrity of the skeletal muscle cell membranes.[34](#jcsm12068-bib-0034){ref-type="ref"} A previous study in patients with neuromuscular diseases has shown a decline of phase angle in parallel with disease progression that was accompanied by a subsequent decline of muscle strength and quality of muscle tissue.[45](#jcsm12068-bib-0045){ref-type="ref"} Therefore our data suggest lower CAF22 to indicate a better cellular integrity of muscle tissue.

The present study had same limitations. As mentioned above, renal function may be a relevant confounder of CAF 22 levels. Further, BIA assessment may provide only limited information on body composition and more detailed information on tissue distribution and composition may be desirable. Previous studies comparing body composition assessment by BIA and dual‐energy X‐ray absorptiometry DEXA, or by BIA and magnet resonance imaging MRI, confirmed reliable agreement between these methods.[46](#jcsm12068-bib-0046){ref-type="ref"}, [47](#jcsm12068-bib-0047){ref-type="ref"}, [48](#jcsm12068-bib-0048){ref-type="ref"}, [49](#jcsm12068-bib-0049){ref-type="ref"}, [50](#jcsm12068-bib-0050){ref-type="ref"} Another study examining muscle mass assessed by BIA and MRI indicated a strong relation between muscle mass and body resistance.[49](#jcsm12068-bib-0049){ref-type="ref"} However, underestimation of the fat mass and over predicting of the fat‐free mass assessed by BIA has been reported.[47](#jcsm12068-bib-0047){ref-type="ref"} In addition, the presence of oedema may influence BIA measurements. The effect of the whole body water changes and its dependence from the sodium plasma concentrations has been discussed previously.[51](#jcsm12068-bib-0051){ref-type="ref"} However, in the present study patients were free of peripheral oedema and sodium plasma levels remained unchanged suggesting stable fluid balance during the observation period.

In conclusion, CAF22 serum levels were elevated in the subacute phase after acute stroke and fell during rehabilitation. Associations between CAF22 and parameters of physical performance, muscle strength, and muscle membrane integrity have been observed. In multivariable analysis recovery of increased CAF22 levels was independently associated with improved hand grip strength only in those patients who showed increasing lean tissue during rehabilitation but not in the entire cohort. The present data are promising to explore further the role CAF22 as a potential serum marker for monitoring muscle status in patients after stroke. Further studies are warranted including optimization of the analytic assay of CAF to evaluate the role of CAF22 as a serum marker of muscle wasting in stroke patients.
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